Option chain shows key data for Anglo American Platinum's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Anglo American Platinum.

Anglo American Platinum (OTC:ANGPY) Stock, Option Chain

Anglo American Platinum Ltd is the world's primary producer of Platinum Group Metals, which includes platinum, palladium, rhodium, iridium, ruthenium, and osmium. The company also produces base metals including copper, nickel, cobalt sulphate, sodium sulphate, chrome, and other precious metals. The primary uses of platinum group metals include jewellery, autocatalytic converters, fuel cells, air- and water-purification units, heart pacemakers, computer screens, hard disks, and fertilisers. The mining operations include managed mines, joint-venture mines, and associate mines across South Africa and Zimbabwe.

mining shutter

Analyst Color

Government

Regulations

Commodities

Markets

Analyst Ratings

ANGPY

GLNCY

KIROY

NGLOY

SOUHY

RBC analyst says Glencore and Anglo American make a better match for potential bidding war for Anglo, with potential for higher synergies.

Glencore-Anglo American Tie-Up Makes More Sense Than BHP Offer, Analyst Says

AngloAmerican.CooperMine.Chile_.CompanyFlickrsite

News

Sector ETFs

ETFs

ANFGF

COPJ

COPP

COPX

GOLD

ICOP

LUNMF

VALE

Multinational miner BHP&#39;s bid for Anglo American may not be enough as other miners are likely to make rival bids for copper assets. Global demand for copper is expected to increase for clean energy.

Copper Is A Hot Commodity: Bidding War for Anglo American May Emerge After BHP&#39;s &#39;Low Ball&#39; Offer — &#39;Let The Games Begin&#39;

Legal

General

AIQUF

AIQUY

DDAIF

DMLRY

EQNR

SHEL

STOHF

TKAMY

TYEKF

Thirty-four investors managing more than $7 trillion in assets have warned 17 of Europe&#39;s most prominent companies that they could challenge board directors over their accounting of climate risks.

Investors Write To 17 European Companies In Campaign For Climate Goal-Aligned Accounts: Reuters

ANGLO AMER PLTNM SPNS/ADR by Anglo American Platinum Ltd.

Anglo American Platinum Ltd

Dividends

Dillard's Declares Record $25 Special Dividend And Regular $0.25 Quarterly Payout As Company Rewards Shareholders And Associates

Matthews International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MATW#NASDAQ">MATW</a>) announced its Q4 earnings on Thursday, November 21, 2024 at 04:15 PM.
Here's a breakdown of the earnings report.
<h3>Earnings</h3>
Matthews International beat estimated earnings by 45.0%, reporting an EPS of $0.55 versus an estimate of $0.38.
Revenue was down $33.47 million from the same period last year.
<h3>Performance in Previous Earnings</h3>
The company beat on EPS by $0.01 in the last quarter, resulting in a 5.0% drop share price change the following day.
Here's a look at Matthews International's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.55</td>
<td>0.45</td>
<td>0.37</td>
<td>0.90</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.56</td>
<td>0.69</td>
<td>0.37</td>
<td>0.96</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>450.12M</td>
<td>469.38M</td>
<td>437.80M</td>
<td>483.00M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>427.88M</td>
<td>471.22M</td>
<td>449.99M</td>
<td>480.17M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Matthews International <a href="https://www.benzinga.com/quote/MATW/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

MATW

Matthews International Earnings Analysis: Q4 Recap

Gap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) released its Q3 earnings on Thursday, November 21, 2024 at 04:15 PM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Gap beat estimated earnings by 24.0%, reporting an EPS of $0.72 versus an estimate of $0.58.
Revenue was up $62.00 million from the same period last year.
<h3>Past Earnings Performance</h3>
In the previous quarter, the company beat on EPS by $0.14, resulting in a 2.0% drop change in the share price the following day.
Here's a look at Gap's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.40</td>
<td>0.14</td>
<td>0.23</td>
<td>0.18</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.54</td>
<td>0.41</td>
<td>0.49</td>
<td>0.59</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>3.63B</td>
<td>3.29B</td>
<td>4.22B</td>
<td>3.61B</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>3.72B</td>
<td>3.39B</td>
<td>4.30B</td>
<td>3.77B</td>
</tr>
</tbody>
</table>

To track all earnings releases for Gap <a href="https://www.benzinga.com/quote/GAP/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Summary: Gap Q3

WIIM

BGC Group shares are trading lower after CEO Howard W. Lutnick announced President-elect Trump's plan to nominate him as Secretary of Commerce. Lutnick intends to step down from positions at Cantor, BGC and Newmark and divest interests.

Bitdeer Technologies Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) ("Bitdeer" or the "Company"), a world-leading technology company for blockchain and high-performance computing, today announced that it intends to offer, subject to market conditions and other factors, US$360.0 million principal amount of Convertible Senior Notes due 2029 (the "notes") in a private placement (the "offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The Company also intends to grant the initial purchasers of the notes an option to purchase, within a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional US$40.0 million principal amount of notes.
The notes will be general senior unsecured obligations of the Company and will accrue interest payable semiannually in arrears. Upon conversion, the Company will pay or deliver, as the case may be, cash, Class A ordinary shares par value US$0.0000001 per share, of the Company (the "Class A ordinary shares") or a combination of cash and Class A ordinary shares, at its election. The interest rate, initial conversion rate, repurchase or redemption rights and certain other terms of the notes will be determined at the time of pricing of the offering.

Offerings

BTDR

Bitdeer Announces Proposed Private Placement Of $360M Of Convertible Senior Notes Due 2029

Casella Waste Systems, Inc. ("Casella") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWST#NASDAQ">CWST</a>), a regional solid waste, recycling and resource management services company, today announced an offering of up to $45.0 million aggregate principal amount of the Finance Authority of Maine (the "Authority") Solid Waste Disposal Revenue Bonds (Casella Waste Systems, Inc. Project) Series 2024 (the "Bonds") under an indenture between the Authority and the bond trustee. The Bonds will be guaranteed under a guaranty (the "Guaranty") by substantially all of Casella's subsidiaries (the "Guarantors"), as required by the terms of the financing agreement between the Authority and Casella (the "Financing Agreement"), pursuant to which the Authority will loan the proceeds of the Bonds to Casella.
Casella intends to use the proceeds of the Bonds to fund the costs of certain qualifying capital projects in the State of Maine, to pay certain costs of issuance, and to refinance and repay in full on the stated maturity date of January 1, 2025 (required to be paid on January 2, 2025 under the applicable indenture) the Authority's Solid Waste Disposal Revenue Bonds (Casella Waste Systems, Inc. Project) Series 2005 (the "2005 Bonds") previously issued to finance certain project costs and costs of issuance under an indenture between the Authority and the bond trustee dated as of December 1, 2005, as amended.
The exact terms and timing of the offering of the Bonds will depend upon market conditions and other factors. There can be no assurance that all approvals with respect to the Bonds will be received, that all other conditions to the issuance of the Bonds will be satisfied or that the offering will be completed.
The Bonds will not be a general obligation of the Authority and will not constitute indebtedness of or a charge against the general credit of the Authority. The Bonds will not be a debt of the State of Maine or any political subdivision of the State of Maine and will be payable solely from any remarketing proceeds and from amounts received from Casella under the terms of the Financing Agreement and from the Guarantors under the Guaranty.

CWST

Casella Waste Systems Announces An Offering Of Up To $45M Aggregate Principal Amount Of The Finance Authority Of Maine Solid Waste Disposal Revenue Bonds Series 2024 Under An Indenture Between The Authority And The Bond Trustee

SPI Energy Announces Nasdaq Delist Determination Notice

KSCP

Knightscope Announces Proposed Public Offering Of Class A Common Stock And Pre-Funded Warrants For Working Capital Needs

Phoenix Motor Announces Nasdaq Delisting Notice

The participant in Neurogene's ongoing Phase 1/2 clinical trial for Rett syndrome who was dosed on November 5 with 3E15 vg of NGN-401 and was previously reported to be in critical condition, has died following complications from a rare and life-threatening hyperinflammatory syndrome associated with systemic exposure to high doses of adeno-associated virus (AAV).
Neurogene will also incorporate the 1E15 vg dose in its future registrational trial design planning.
&nbsp;
 &nbsp;

NGNE

Neurogene Says FDA Allowed Company To Proceed With Phase 1/2 Trial Using 1E15 vg Dose For Both Pediatric And Adolescent/Adult Cohorts

Gap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) reported quarterly earnings of $0.72 per share which beat the analyst consensus estimate of $0.57 by 26.32 percent. The company reported quarterly sales of $3.829 billion which beat the analyst consensus estimate of $3.812 billion by 0.45 percent. This is a 1.65 percent increase over sales of $3.767 billion the same period last year.

Earnings Beats

Gap Q3 2024 GAAP EPS $0.72 Beats $0.57 Estimate, Sales $3.829B Beat $3.812B Estimate

Stock Split

CETX

Cemtrex Board Approves 1-For-35 Reverse Stock Split To Begin Trading November 26 Under Same CETX Symbol

Neurogene Says Participant In Ongoing Phase 1/2 Clinical Trial For Rett Syndrome Who Was Dosed On November 5 With 3E15 vg Of NGN-401 And Was Previously In Critical Condition, Has Died

CAMP

CAMP4 Therapeutics Q3 EPS $(24.19), Ended Quarter With $2.5M In Cash And Cash Equivalents

<ul>
<li>Cash and cash equivalents at €13.9 million, as of September 30, 2024.</li>
<li>Revenues of €1.3 million for the first nine months of 2024.</li>
<li>On July 18, 2024, Inventiva issued royalty certificates for an amount of €20.1 million.</li>
<li>Considering the receipt of €94.1 million in gross proceeds from the closing of the first part of the first tranche of the equity raise announced on October 14, 20242 and the receipt of the $10 million milestone payment under the amended license and collaboration agreement with CTTQ on November 18, 2024, the Company estimates that its cash, cash equivalents and deposits would enable it to finance its operations until the end of the second quarter of 20253.</li>
</ul>
 &nbsp;

Inventiva Reports Revenues Of €1.3 Million For The First 9-Months Of 2024

Copart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>) reported quarterly earnings of $0.37 per share which met the analyst consensus estimate. The company reported quarterly sales of $1.146 billion which beat the analyst consensus estimate of $1.100 billion by 4.19 percent. This is a 12.35 percent increase over sales of $1.020 billion the same period last year.

CPRT

Copart Q1 2025 GAAP EPS $0.37, Inline, Sales $1.146B Beat $1.100B Estimate

Regulators are looking to block Google <a href="https://www.benzinga.com/news/large-cap/23/10/35474706/googles-ai-ambitions-grow-with-major-investment-in-openai-rival-anthropic">from investing $2 billion</a> in Antrophic, a Jeff Bezos-backed rival to artificial intelligence (AI) innovator OpenAI. 
What Happened: The U.S. Department of Justice (DOJ) recommended in <a href="https://www.benzinga.com/tech/24/11/42105079/googles-unlawful-behavior-stifles-market-entry-for-rivals-doj-says-alphabet-must-sell-chrome-to-end-search-monopoly">a court filing Wednesday</a> that Alphabet Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google divest its Chrome browser to dismantle its monopoly on online search. 
It doesn&#8217;t end there. Google should be barred from doing any deals with companies that control where consumers search for information, regulators say. That includes AI products. This puts Google's Anthropic investment at risk, according to <a href="https://www.bloomberg.com/news/articles/2024-11-21/us-justice-department-seeks-to-unwind-google-s-anthropic-deal">Bloomberg</a>, citing unnamed sources.
Also Read: <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/11/42121215/nvidia-post-earnings-jitters-can-nvda-stock-regain-its-ai-fueled-momentum">Nvidia&#8217;s Post-Earnings Jitters: Can NVDA Stock Regain Its AI-Fueled Momentum?</a>
Google boasts over 91% global market share when it comes to online search, per&nbsp;<a href="https://gs.statcounter.com/search-engine-market-share" target="_blank" rel="noreferrer noopener">GlobalStats</a>.&nbsp;
Why It Matters: Google needs Anthropic, or startups like it. Without it, Google is at a disadvantage, considering every major tech company is essentially in an AI arms race. 
Since OpenAI&#8217;s ChatGPT launch in late 2022, tech giants have heavily invested in AI startups.
But Google&#8217;s Anthropic deal is raising concerns overseas as well.
Last month, U.K. antitrust officials announced an investigation into whether Google&#8217;s pursuit of Anthropic <a href="https://www.gov.uk/cma-cases/alphabet-inc-google-llc-slash-anthropic-merger-inquiry" target="_blank" rel="noreferrer noopener">could harm competition</a>. 
Meanwhile, Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) managed to avoid scrutiny. <a href="https://www.benzinga.com/m-a/24/09/41067395/amazons-partnership-with-jeff-bezos-backed-anthropic-gets-green-signal-from-uk-competition-watchdog" target="_blank" rel="noreferrer noopener">The UK&#8217;s competition regulator</a> recently approved the partnership between Amazon and Anthropic, despite the Seattle-based company&#8217;s significant $4 billion investment in the company.
Britain&#8217;s Competition and Markets Authority (CMA) confirmed the partnership does not fall under its jurisdiction.
Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) also appeased regulators when it <a href="https://www.benzinga.com/markets/equities/24/07/39703459/microsoft-relinquishes-observer-role-on-openais-board-says-it-is-confident-in-companys-direction" target="_blank" rel="noreferrer noopener">relinquished its board observer</a> role at OpenAI. The Redmond, Washington-based company invested over $10 billion in the AI startup.
What&#8217;s Next: A decision on whether the UK will require further investigation is expected by Dec. 19.
In the U.S., Google plans to appeal Judge Amit Mehta&#8216;s <a href="https://www.benzinga.com/government/24/08/40169996/alphabet-loses-antitrust-suit-over-google-search-dominance-report">antitrust ruling in August</a>. 
Mehta&#8217;s decision could ultimately lead to Google divesting segments of its business, <a href="https://www.benzinga.com/government/regulations/24/11/42119020/alphabet-bleeds-over-120-billion-in-market-value-eyes-worst-day-in-10-months-after-doj-demands-google-chrome-sale">including Chrome</a>.
Price Action: Alphabet was down 4.5% to $169.24 on Thursday.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42121525/microstrategy-surges-674-in-2024-5-etfs-that-benefit-from-mstrs-bitcoin-driven-growth">MicroStrategy Surges 674% In 2024: 5 ETFs That Benefit From MSTR&#8217;s Bitcoin-Driven Growth</a></li>
</ul>
Image: Shutterstock

Politics

Tech

AMZN

GOOG

GOOGL

MSFT

Google, Anthropic Deal In Jeopardy As US Justice Department Looks To Snap Online Search Monopoly

Contracts

SNOA

Sonoma Pharmaceuticals Terminates Agreement With EMC Pharma After It Did Not Meet Minimum Purchase Requirements

Buybacks

EGAN

eGain Board Approves Extension To Stock Repurchase Program From Nov. 14 Until The Earlier Of The Date The Aggregate Amount Of Shares That Can Be Repurchased Under The Stock Repurchase Program Have Been Repurchased And November 14, 2025

Authorization is based on results from the Phase 3 CARTITUDE-4 (MMY3002) study, which showed treatment with CARVYKTI&#xAE; reduced the risk of disease progression or death by 74 per cent compared to standard of care.1
TORONTO, Nov. 21, 2024 /CNW/ - Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced today that Health Canada has issued a Notice of Compliance (NOC) for CARVYKTI&#xAE; (ciltacabtagene autoleucel) for the treatment of adult patients with multiple myeloma who have received one to three prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide.1&nbsp;With this approval, CARVYKTI&#xAE; becomes the first and only B-cell Maturation Antigen&nbsp;(BCMA)-targeted therapy approved for the treatment of patients with multiple myeloma as early as second line.
CARVYKTI&#xAE; previously received a Notice of Compliance with conditions (NOC/c) from Health Canada for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 antibody, and who are refractory to their last treatment.1
Canada's Drug Agency (CDA-AMC) has recently recommended CARVYKTI&#xAE; for reimbursement with conditions for eligible patients who have received one to three prior lines of therapy. In its rationale for the recommendation, CDA-AMC pointed out that the CARTITUDE-4 trial demonstrated that treatment with CARVYKTI&#xAE;, compared to standard of care, was associated with statistically significant and clinically meaningful improvements in progression-free survival (PFS) in eligible patients. This builds on their prior recommendation for reimbursement with conditions for CARVYKTI&#xAE; in 2023 in eligible patients who have received at least three prior lines of therapy, based on the results of the CARTITUDE-1 trial. Johnson &amp; Johnson is actively working with the pan-Canadian Pharmaceutical Alliance to negotiate reimbursement for CARVYKTI&#xAE; to enable public access.

Biotech

Johnson & Johnson Announces Health Canada Authorizes CARVYKTI For Patients With Relapsed Or Refractory Multiple Myeloma Who Have Received 1-3 Prior Lines Of Therapy, Including A Proteasome Inhibitor And An Immunomodulatory Agent, And Who Are Refractory To Lenalidomide

BHP, Anglo American merger looks unlikely as talks fail to progress - FT

Anglo American Platinum: Forced Selling Risk On Demerger

Amplats guides for 15%-25% lower half-year earnings on lower platinum metals prices

Anglo American Platinum reports interim 1H results

Anglo American Platinum Limited (ANGPY) H1 2024 Earnings Call Transcript

Anglo American Platinum goes ex dividend tomorrow

abrdn Emerging Markets Fund Q2 2024 Commentary

Anglo raises $400M in discounted sale of Amplats shares ahead of full exit

Anglo American Platinum: Going Through A Highly Uncertain Period

Anglo American Platinum: The Best PGM Miner; Rating Upgrade

AAUKF

AGPPF

BKRKF

BKRKY

BOLSY

DLEGF

HKXCF

HKXCY

LAAOF

MAHMF

MDTTF

PALL

PIAIF

PNGAY

PPCCF

PPCCY

PPLT

SGOL

SIVR

TSMWF

UCLQF

Anglo American Platinum

JP Morgan

Comments

Anglo American Platinum

Anglo American Platinum (ANGPY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga